GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Alphatec Holdings Inc (NAS:ATEC) » Definitions » Debt-to-EBITDA
中文

Alphatec Holdings (Alphatec Holdings) Debt-to-EBITDA

: -4.87 (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Alphatec Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.0 Mil. Alphatec Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $534.7 Mil. Alphatec Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-111.3 Mil. Alphatec Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -4.87.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Alphatec Holdings's Debt-to-EBITDA or its related term are showing as below:

ATEC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.9   Med: -2.39   Max: 3.9
Current: -4.9

During the past 13 years, the highest Debt-to-EBITDA Ratio of Alphatec Holdings was 3.90. The lowest was -4.90. And the median was -2.39.

ATEC's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs ATEC: -4.90

Alphatec Holdings Debt-to-EBITDA Historical Data

The historical data trend for Alphatec Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphatec Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.45 -0.79 -3.33 -3.86 -4.90

Alphatec Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.54 -4.30 -3.70 -5.94 -4.87

Competitive Comparison

For the Medical Devices subindustry, Alphatec Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphatec Holdings Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Alphatec Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alphatec Holdings's Debt-to-EBITDA falls into.



Alphatec Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Alphatec Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.967 + 534.712) / -110.592
=-4.90

Alphatec Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.967 + 534.712) / -111.288
=-4.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Alphatec Holdings  (NAS:ATEC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Alphatec Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alphatec Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphatec Holdings (Alphatec Holdings) Business Description

Traded in Other Exchanges
Address
1950 Camino Vida Roble, Carlsbad, CA, USA, 92008
Alphatec Holdings Inc is a medical technology company focused on the design, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Executives
David Sponsel officer: EVP, Sales C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Patrick Miles director, officer: Executive Chairman 7475 LUSK BLVD., SAN DIEGO CA 92121
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
David H Mowry director 9775 TOLEDO, IRVINE CA 92618
Evan Bakst director 225 CENTRAL PARK WEST, APT. 1605, NEW YORK NY 10024
Jennifer N. Pritzker 10 percent owner C/O SQUADRON CAPITAL LLC, 104 S. MICHIGAN AVENUE, SUITE 500, CHICAGO IL 60603
Tyson Eliot Marshall officer: GENERAL COUNSEL & CORP. SEC. 10680 TREENA STREET, SUITE 500, SAN DIEGO CA 92131
Craig E Hunsaker officer: See Remarks C/O ALPHATEC HOLDINGS, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Paul Segal 10 percent owner 1700 BROADWAY, 35TH FLOOR, NEW YORK NY 10019
L-5 Healthcare Partners, Llc 10 percent owner, other: Director by deputization 1700 BROADWAY, 35TH FLOOR, NEW YORK NY 10019
John Todd Koning officer: Chief Financial Officer C/O MASIMO CORPORATION, 52 DISCOVERY, IRVINE CA 92618
David R Pelizzon director, 10 percent owner 2850 FRONTIER DR, WARSAW IN 46582
Scott Lish officer: SVP, Development C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD CA 92008